Pharma Technology Focus: Taming big pharma
In this issue: breakthroughs in HIV treatment, understanding drug-resistant TB, the fallout from...
Focus:
Most Read
Latest Content
Are M&As the Key to Securing Growth in the Orphan Drugs Sector?
The orphan drug market can be an alluringly lucrative sector. Most big pharma corporations inherit these specialty business units through mergers and acquisitions (M&As). Yet it is not a viable sector for all pharmaceutical companies as it requires specialist capabilities.
2019 Temperature Control Catalogue
Huber’s new temperature control catalogue 2019 has been completely revised and highlights a wide range of equipment for in laboratory, mini plant and production, including chillers and high dynamic temperature control systems, as well as classical baths and circulators for working temperatures from -125°C to +425 °C.
Electrolab: Pharmaceutical testing equipment
Electrolab manufactures state-of-art pharmaceutical testing equipment. As part of the company’s global network of distributors, DJA supplies Electolab’s testing solutions to the US and Canada.
Restless Leg Syndrome sufferers not receiving accurate diagnosis
A significantly high proportion of the population in the West experiences restless leg symptoms, but less than one third receives an accurate diagnosis.
Pharma Technology Focus: Taming big pharma
In this issue: breakthroughs in HIV treatment, understanding drug-resistant TB, the fallout from Teva’s price fixing scandal, tackling unlicensed stem cell clinics, and much more.
NSF’s Laurence Matheron and Robyn Meurant Participate in MedFIT Panels in Lille, France
Two NSF medical device experts took part in panel discussions on June 25 at the MedFIT conference in Lille, France.
Measurement Uncertainty in GxP Temperature Mapping
In the real world of GMP, GDP and GLP, is expressing measurement uncertainty in mapping (and not just in calibration) an overkill, or there is some reason to it?
FDA approves Grifols’ Xembify for immunodeficiencies
Spanish plasma-derived medicine specialist Grifols has announced that the US Food and Drug Administration (FDA) has approved its Xembify (immune globulin subcutaneous, human- klhw) for patients over two years old with primary immunodeficiencies.
Annex 1 and Continuing Monitoring Solutions
The upcoming revision and the current draft of Annex 1 indicate that continuous monitoring is a requirement in cleanrooms. The question is how to do that effectively and in an acceptable manner.
Understanding Sucrose: Matching Sucrose Quality to Functional Need
In this white paper, Trevor Calkins and Nancy Coffman study the uses of parenteral-grade sucrose in biomolecule development.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
Close
Close
Close
